ReviewCureus2025
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and diabetes are common among patients undergoing total hip arthroplasty (THA) and are associated with adverse outcomes. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were originally developed for glycaemic control but have recently been approved for weight reduction. Given these dual metabolic effects, their perioperative use is of growing interest. Despite this, the impact of GLP-1 RAs on post-operative outcomes remains underexplored. This systematic review and meta-analysis aim to address this evidence gap. A literature search was conducted in MEDLINE, PubMed, Embase, and CENTRAL from inception to 1st June 2025. Studies comparing outcomes between GLP-1 RA users and non-users in adults (≥18 years) undergoing primary THA were included. Primary outcomes included medical and surgical complications. Secondary outcomes included hospital-related measures such as 90-day readmissions and length of stay. Risk of bias was assessed using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool, and the certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Six retrospective cohort studies, all conducted in the United States, met the inclusion criteria and included 11,869 GLP-1 RA users and 22,777 controls. GLP-1 RAs use was associated with a statistically significant reduction in 90-day readmission rates (odds ratio (OR) 0.81, 95% confidence interval (CI) 0.69-0.94, p = 0.007; I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.